![]() iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare's vision is to keep the world visible to everyone, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. ICare is a Finnish company that develops and manufactures innovative retinal imaging devices and software solutions for the diagnosis and screening of eye diseases. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V. ![]() In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care. ![]() iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. Revenio is a leading company in the global market for ophthalmological devices and software solutions. We are convinced that it will add value to the daily work of optometrists and ophthalmologists," says Alexandre Le Guilcher, Innovation Director at Evolucare Technologies. The integration of OphtAI into iCare ILLUME proves that AI can be intelligently integrated into practitioners' tools. "Based on our previous partnerships, we have seen that the OphtAI solution is perfectly in line with the needs of optical professionals, making AI increasingly essential in healthcare. We see opportunities for expansion into new geographical areas through our collaboration," says Pirjo Kortteisto, Business Line Director at Icare Finland. OphtAI is particularly strong in the French market, where EDC Lamy will continue as our valued exclusive distributor for imaging devices. All our solutions have top-notch performance, and we have validated the OphtAI solution's performance in diabetic retinopathy screening. Through this partnership, we further strengthen our offering by providing our customers with more options, each with its benefits. We are one of the leading developers of eye diagnostic devices, and our software solutions are increasingly important in eye care pathways. "Our mission is to keep the wonderful world visible to everyone. This holistic solution optimizes patient care pathways and the processes of eye care professionals. AI enables the efficient processing of large numbers of images, thereby improving screening accessibility. The iCare ILLUME solution supports clinical decision-making and is based on high-quality image data produced by iCare's retinal imaging devices and cloud-based software solutions. The iCare ILLUME retinal screening solution uses AI-generated image analysis for diabetic retinopathy screening and, in the future, for other eye diseases. OphtAI is one of the most advanced AI retinal image analysis providers. iCare will now offer OphtAI analysis in EMEA and Canada for its iCare ILLUME retinal screening solution based on retinal images. ICare and OphtAI, a French Evolucare Technologies company, have launched a distribution partnership. ICare and Evolucare have launched a distribution partnership in AI solutions Revenio Group Corporation, Press release, May 8, 2023 at 10.00 a.m.
0 Comments
Leave a Reply. |